Press Releases

Month Year

Month Year

Jul 1, 2020

Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders

- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -
Jun 2, 2020

Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock
Jun 2, 2020

Evofem Announces Proposed Public Offering of Common Stock
May 22, 2020

U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

- A New Class of Female-Controlled Birth Control for Use In-The-Moment -
May 13, 2020

Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference

Show per page